NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Goldenrod Therapeutics, Inc.

Goldenrod Therapeutics, Inc.

Private
Houston, TexasHealthcare & Life Scienceshttps://goldenrodtx.com/

Last Round

Seed

Jun 3, 2026

Total Funding Raised

$920,000

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Goldenrod Therapeutics, Inc. is a biotechnology company developing next-generation, brain-penetrant phosphodiesterase 4 (PDE4) inhibitors for serious neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

PDE4 inhibitorsmall molecule drugFriedreich's Ataxianeurodegenerative diseaseneuroinflammationCNS therapeuticsrare diseaseorphan drugbrain-penetrantdrug discoverypreclinical biotechbiotechdrug licensingMultiple SclerosisSubstance Use DisorderAlzheimer's disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Goldenrod Therapeutics, Inc. Comparables

Compare Goldenrod Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Goldenrod Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enthorin Therapeutics
83%
Shionogi & Co.
74%
PTC Therapeutics Inc
69%

Goldenrod Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 3, 2026
GrantNov 5, 2024
GrantOct 10, 2024
GrantJul 14, 2021

Goldenrod Therapeutics, Inc. Investors

Notable investors and investment history

Goldenrod Therapeutics, Inc. investors
InvestorRounds
United States Department of DefenseGrant
Fannin Innovation StudioSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 3, 2026

    $3.2M seed round completed.

Goldenrod Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Goldenrod Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Goldenrod Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHouston, Texas
Year Founded2020
Last FundingJun 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.